on DBV TECHNOLOGIES (EPA:DBV)
DBV Technologies General Meeting on June 3, 2026
DBV Technologies, a biopharmaceutical company specializing in pediatric allergies, will hold its Combined General Meeting on June 3, 2026, in Châtillon. Shareholders can consult the preparatory documents on the company's website. A live and recorded webcast will be available, subject to technical conditions. Requests for documents electronically must be made before May 29, 2026. Holders of bearer shares must provide proof of share ownership.
DBV Technologies, listed on Euronext Paris and Nasdaq, is working on innovative treatments such as its VIASKIN platform, which focuses on food allergies. This meeting aims to provide shareholders with an update on the company's progress and projects.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all DBV TECHNOLOGIES news